Hypothesis

Emodin maintains balanced X‑chromosome inactivation (XCI) by suppressing NLRP3‑mediated inflammation, thereby preserving the dosage advantage of X‑linked escapee genes and extending lifespan, particularly in XX individuals.

Rationale

• Inflammatory cytokines such as IL‑1β promote epigenetic drift at the XIST locus, leading to skewed XCI [3].
• Emodin potently inhibits the NLRP3 inflammasome, reducing IL‑1β and caspase‑1 secretion [4].
• Skewed XCI diminishes the expression of protective X‑linked escapees (e.g., KDM6A) that confer neuroprotection and stress resistance [1,2].
• Therefore, by dampening inflammasome activity, emodin could sustain the mosaicism that underlies the female longevity advantage.

Novel Mechanistic Insight

Beyond inflammasome inhibition, emodin acts as a weak histone deacetylase (HDAC) inhibitor, increasing acetylation at the XIST promoter and facilitating its repression in a subset of cells, which favors a more uniform escapee expression pattern across tissues.

Testable Predictions

1. In aged XX mice, chronic emodin treatment will reduce XCI skewing measured by allele‑specific RNA‑seq of escapee genes compared with vehicle.
2. This effect will be absent in NLRP3‑knockout mice, indicating dependence on inflammasome suppression.
3. Emodin‑treated XX mice will show higher KDM6A expression in brain and improved cognitive performance, whereas XY mice will exhibit minimal change.
4. Longitudinal survival analysis will reveal a significant lifespan extension in XX, but not XY, emodin‑treated cohorts.

Experimental Design

• Cohorts: C57BL/6 XX and XY mice (n=30 per group) receiving emodin (50 mg/kg/day) or control chow from 12 months of age.
• Readouts:
  • XCI skewing (RNA‑seq allele‑specific expression of KDM6A, USP9X) at 18 and 24 months.
  • NLRP3 inflammasome activity (caspase‑1 cleavage, IL‑1β levels) in serum and microglia.
  • HDAC activity in brain extracts.
  • Behavioral assays (Morris water maze) and survival monitoring.
• Controls: NLRP3‑KO XX mice treated with emodin to test pathway specificity.

Implications

If validated, this hypothesis would reposition emodin (and similar inflammasome inhibitors) as epigenogerontological agents that preserve sex‑chromosome dosage balance, offering a mechanistic bridge between inflammation control and the inherent longevity advantage of the XX genome.